These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19111876)

  • 1. Curing APL: differentiation or destruction?
    Kogan SC
    Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T; Sawaki K
    J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
    Jing Y; Xia L; Waxman S
    Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 12. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U; Pelosi E
    Adv Exp Med Biol; 2024; 1459():321-339. PubMed ID: 39017850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
    Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
    Zhu J; Lallemand-Breitenbach V; de Thé H
    Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
    Jing Y; Wang L; Xia L; Chen GQ; Chen Z; Miller WH; Waxman S
    Blood; 2001 Jan; 97(1):264-9. PubMed ID: 11133770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.